EGFR and colorectal cancer: Although KRAS mutations are consistently associated with reduced overall and progression-free survival (PFS) and increased treatment failure rates among patients with advanced colorectal cancer treated with anti-EGFR antibodies (Dahabreh et al, 2011), no genetic and molecular markers for BV have been found.